Cellular and Organismal Toxicity of the Anti-Cancer Small Molecule, Tolfenamic Acid: a Pre-Clinical Evaluation
Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA o...
Saved in:
Published in | Cellular physiology and biochemistry Vol. 32; no. 3; pp. 675 - 686 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
Cell Physiol Biochem Press GmbH & Co KG
01.01.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice. |
---|---|
AbstractList | Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice. The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre-clinical studies in cancer. Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice. |
Author | Lee, Chris M. Connelly, Sarah F. Adwan, Lina Basha, Riyaz Kayaleh, Omer Sankpal, Umesh T. Eslin, Don Lichtenberger, Lenard M. Goodison, Steven Zawia, Nasser H. Sutphin, Robert |
Author_xml | – sequence: 1 givenname: Umesh T. surname: Sankpal fullname: Sankpal, Umesh T. – sequence: 2 givenname: Chris M. surname: Lee fullname: Lee, Chris M. – sequence: 3 givenname: Sarah F. surname: Connelly fullname: Connelly, Sarah F. – sequence: 4 givenname: Omer surname: Kayaleh fullname: Kayaleh, Omer – sequence: 5 givenname: Don surname: Eslin fullname: Eslin, Don – sequence: 6 givenname: Robert surname: Sutphin fullname: Sutphin, Robert – sequence: 7 givenname: Steven surname: Goodison fullname: Goodison, Steven – sequence: 8 givenname: Lina surname: Adwan fullname: Adwan, Lina – sequence: 9 givenname: Nasser H. surname: Zawia fullname: Zawia, Nasser H. – sequence: 10 givenname: Lenard M. surname: Lichtenberger fullname: Lichtenberger, Lenard M. – sequence: 11 givenname: Riyaz surname: Basha fullname: Basha, Riyaz email: riyazbasha@yahoo.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24030139$$D View this record in MEDLINE/PubMed |
BookMark | eNptkMlv1DAUhy3Uii5w4I6QJU5IBLyO7d6GqJtU1EqUc_TiZXDx2CMng-h_30BoTpze9r3v8DtBB7lkj9AbSj5RKs1nQgiXQij6Ah1TwWhjlNIHU0-obLTR6gidDMMDmUZl2Et0xAThhHJzjHLrU9onqBiyw7d1AzkOW0j4vvyONo6PuAQ8_vB4ncfYtJCtr_jbBCT8tSRv98l_nNgUfIZttHhtozvDgO-qb9oUc7ST6_wXpD2MseRX6DBAGvzrf_UUfb84v2-vmpvby-t2fdNYweXYWBt6Z5SW2lDpNdGWMAErYYN22mvKOISgA2UebE8pc6rvjZXAQKx6C5qfouvZ6wo8dLsat1AfuwKx-7soddNBHaNNvtNagKN-pRQXAqgBxwNYJoFKQpldTa4Ps8vWMgzVh8VHSfcn_27Jf2Lfzexu32-9W8jnwCfg7Qz8hLrxdQGW__f_Pbd3X2ai27nAnwBQDJZa |
CitedBy_id | crossref_primary_10_1007_s13277_016_5290_9 crossref_primary_10_1016_j_critrevonc_2018_03_016 crossref_primary_10_1007_s11064_018_2615_7 crossref_primary_10_1016_j_procbio_2019_10_022 crossref_primary_10_1007_s13277_015_3924_y crossref_primary_10_18632_oncotarget_6553 crossref_primary_10_1016_j_neuropharm_2014_01_009 crossref_primary_10_1016_j_cbi_2021_109537 crossref_primary_10_1007_s13277_015_3775_6 crossref_primary_10_1155_2019_4032428 crossref_primary_10_1186_s12576_020_00757_y crossref_primary_10_18632_oncotarget_14651 crossref_primary_10_1007_s00580_019_03025_7 crossref_primary_10_1007_s10495_018_1508_1 crossref_primary_10_1111_jnc_12960 crossref_primary_10_1016_j_pharmthera_2015_05_008 |
ContentType | Journal Article |
Copyright | 2013 S. Karger AG, Basel 2013 S. Karger AG, Basel. |
Copyright_xml | – notice: 2013 S. Karger AG, Basel – notice: 2013 S. Karger AG, Basel. |
DBID | M-- CGR CUY CVF ECM EIF NPM AAYXX CITATION DOA |
DOI | 10.1159/000354471 |
DatabaseName | Karger Journals Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: M-- name: Karger Journals Open Access url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Biology |
EISSN | 1421-9778 |
EndPage | 686 |
ExternalDocumentID | oai_doaj_org_article_884ad1e677344a19ad3fac25a15012c6 10_1159_000354471 24030139 354471 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: P30 DK056338 |
GroupedDBID | --- 0R~ 0~B 29B 30W 326 36B 3O. 4.4 53G 5GY 5VS 6J9 8UI AAFWJ AAYIC ACGFO ACGFS ADBBV AENEX AEYAO AFPKN AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CS3 CYUIP DIK DU5 E0A E3Z EBS EJD EMB EMOBN F5P FB. GROUPED_DOAJ HZ~ IPNFZ KQ8 KUZGX M-- ML- N9A O1H O9- OK1 P2P RIG RKO RNS SV3 UJ6 3V. 7X7 88E 8FI 8FJ ABUWG ADAGL AFKRA AIOBO BENPR BPHCQ BVXVI CAG CCPQU CGR COF CUY CVF ECM EIF FYUFA HMCUK IAO IHR ITC M1P NPM PQQKQ PROAC PSQYO RXVBD UKHRP AAYXX CITATION |
ID | FETCH-LOGICAL-c435t-ccfbd97858915e808c024a64cf8d8e8123aff8f12eacb112d7bb9c5a2a46bca83 |
IEDL.DBID | DOA |
ISSN | 1015-8987 |
IngestDate | Thu Jul 04 20:54:30 EDT 2024 Thu Sep 26 16:46:54 EDT 2024 Sat Sep 28 08:38:49 EDT 2024 Thu Sep 05 19:48:39 EDT 2024 Thu Aug 29 12:04:43 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Small molecule Survivin Tolfenamic acid Sp1 Toxicity |
Language | English |
License | Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. 2013 S. Karger AG, Basel. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c435t-ccfbd97858915e808c024a64cf8d8e8123aff8f12eacb112d7bb9c5a2a46bca83 |
OpenAccessLink | https://doaj.org/article/884ad1e677344a19ad3fac25a15012c6 |
PMID | 24030139 |
PageCount | 12 |
ParticipantIDs | crossref_primary_10_1159_000354471 pubmed_primary_24030139 doaj_primary_oai_doaj_org_article_884ad1e677344a19ad3fac25a15012c6 karger_primary_354471 |
PublicationCentury | 2000 |
PublicationDate | 2013-01-01 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Germany |
PublicationTitle | Cellular physiology and biochemistry |
PublicationTitleAlternate | Cell Physiol Biochem |
PublicationYear | 2013 |
Publisher | Cell Physiol Biochem Press GmbH & Co KG |
Publisher_xml | – name: Cell Physiol Biochem Press GmbH & Co KG |
References | Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective cox-2 inhibitors. JAMA 2001;286:954-959.1150906010.1001/jama.286.8.954 Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G: Aspirin, salicylates, and cancer. Lancet 2009;373:1301-1309.1932854210.1016/S0140-6736(09)60243-9 Abdelrahim M, Baker CH, Abbruzzese JL, Safe S: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and sp protein degradation. J Nat Cancer Inst 2006;98:855-868.1678815910.1093/jnci/djj232 Shukoor MI, Tiwari S, Sankpal UT, Maliakal P, Connelly SF, Siddiqi S, Siddiqi SA, Basha R: Tolfenamic acid suppresses cytochrome p450 2e1 expression in mouse liver. Integr Biol (Camb) 2012;4:1122-1129.2283266010.1039/c2ib20127e Eslin D, Sankpal UT, Lee C, Sutphin RM, Maliakal P, Currier E, Sholler G, Khan M, Basha R: Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma. Mol Carcinog 2013;52:377-386.2221333910.1002/mc.21866 Pathi S, Li X, Safe S: Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (sp) transcription factors. Mol Carcinog 2013, epub ahead of print.2367089110.1002/mc.22010 Wu KK, Liou JY: Cyclooxygenase inhibitors induce colon cancer cell apoptosis via ppardelta -> 14-3-3epsilon pathway. Methods Mol Biol 2009;512:295-307.1934728410.1007/978-1-60327-530-9_16 Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2S-8S; discussion 21S-22S.957231410.1016/S0002-9343(97)00203-9 Choi ES, Shim JH, Jung JY, Kim HJ, Choi KH, Shin JA, Nam JS, Cho NP, Cho SD: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer science 2011;102:742-748.2124141810.1111/j.1349-7006.2011.01871.x Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-286.1185744310.1002/jcp.10068 Eslin D, Lee C, Sankpal UT, Maliakal P, Sutphin RM, Abraham L, Basha R: Anticancer activity of tolfenamic acid in medulloblastoma: A preclinical study. Tumour Biol 2013, epub ahead of print.2368678510.1007/s13277-013-0836-6 Cambell NB, Halushka PV: Lipid derived autocoids. Eicosanoides and platelet activating factor; in Hardman JG, Limbird AE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds): Goodman & gilman's the pharmacological basis of therapeutics. New York, McGraw-Hill, 1996, pp 60-616. Howe LR: Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9:210.1764039410.1186/bcr1678 Klan R, Knispel HH, Meier T: Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol 1993;119:482-485.850943810.1007/BF01215929 Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011;122:163-170.2149689010.1016/j.ygyno.2011.03.014 Huang H, Bihaqi SW, Cui L, Zawia NH: In vitro pb exposure disturbs the balance between abeta production and elimination: The role of abetapp and neprilysin. Neurotoxicology 2011;32:300-306.2131575910.1016/j.neuro.2011.02.001 Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-3232.815973010.1073/pnas.91.8.3228 Darling RL, Romero JJ, Dial EJ, Akunda JK, Langenbach R, Lichtenberger LM: The effects of aspirin on gastric mucosal integrity, surface hydrophobicity and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 2004;127:94-104.1523617610.1053/j.gastro.2004.04.003 Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, Hayashi Y: Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with n-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990;11:393-395.231118110.1093/carcin/11.3.393 Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R: Small molecule tolfenamic acid inhibits pc-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate 2012;72:1648-1658.2247387310.1002/pros.22518 Kovala-Demertzi D, Hadjipavlou-Litina D, Primikiri A, Staninska M, Kotoglou C, Demertzis MA: Anti-inflammatory, antiproliferative, and radical-scavenging activities of tolfenamic acid and its metal complexes. Chem Biodivers 2009;6:948-960.1955173710.1002/cbdv.200800120 Kundu N, Fulton AM: Selective cyclooxygenase (cox)-1 or cox-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002;62:2343-2346.11956094 Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H: Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 2007;110:791-800.1758280210.1002/cncr.22854 Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K: Combined treatment of pancreatic cancer with mithramycin a and tolfenamic acid promotes sp1 degradation and synergistic antitumor activity. Cancer Res 2010;70:1111-1119.2008617010.1158/0008-5472.CAN-09-3282 Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M: Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009;8:533-542.1925842910.1158/1535-7163.MCT-08-0405 Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-205.883456310.1097/00001648-199603000-00017 Sutphin RM, Connelly SF, Lee CM, Sankpal UT, Eslin D, Khan M, Pius H, Basha R: Anti-leukemic response of a nsaid, tolfenamic acid. Target Oncol 2013, epub ahead of print.2360905510.1007/s11523-013-0274-9 Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-met. Carcinogenesis 2009;30:1193-1201.1940693310.1093/carcin/bgp092 Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (cox-2)-selective nonsteroidal anti-inflammatory drug: Independence from cox-2 protein expression. Clin Cancer Res 1997;3:1679-1683.9815550 Gately S, Li WW: Multiple roles of cox-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol 2004;31:2-11.1517962010.1053/j.seminoncol.2004.03.040 Chandrasekharan NV, Simmons DL: The cyclooxygenases. Genome Biol 2004;5:241.1534504110.1186/gb-2004-5-9-241 Murasaki G, Zenser TV, Davis BB, Cohen SM: Inhibition by aspirin of n-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis 1984;5:53-55.669008610.1093/carcin/5.1.53 Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S, Baek SJ: Ese-1/egr-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 2008;7:3739-3750.1907484910.1158/1535-7163.MCT-08-0548 Vane JR: Cox-2 inhibitors: Background knowledge for clinical use. Introduction. Inflamm Res 1998;47:S77.9831327 Lim YJ, Dial EJ, Lichtenberger LM: Advent of novel phosphatidylcholine-associated nonsteroidal antiinflammatory drugs with improved gastrointestinal safety. Gut Liver 2013;7:7-15.2342387410.5009/gnl.2013.7.1.7 Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-245.869484810.1016/0006-2952(96)00181-5 Kourounakis PN, Tsiakitzis K, Kourounakis AP, Galanakis D: Reduction of gastrointestinal toxicity of nsaids via molecular modifications leading to antioxidant anti-inflammatory drugs. Toxicology 2000;144:205-210.1078188910.1016/S0300-483X(99)00208-5 McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-1644.1696883110.1001/jama.296.13.jrv60011 Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA: Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009;18:2726-2733.1975564710.1158/1055-9965.EPI-09-0363 Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R: Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 2012;30:853-861.2119762110.1007/s10637-010-9622-0 Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM: Nsaid injury to the gastrointestinal tract: Evidence that nsaids interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006;58:1421-1428.1713220310.1211/jpp.58.10.0001 Robert A, Schultz JR, Nezamis JE, Lancaster C: Gastric antisecretory and antiulcer properties of pge2, 15-methyl pge2, and 16, 16-dimethyl pge2. Intravenous, oral and intrajejunal administration. Gastroenterology 1976;70:359-370.174967 Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in |
References_xml | |
SSID | ssj0015792 |
Score | 2.153711 |
Snippet | Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at... The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson... |
SourceID | doaj crossref pubmed karger |
SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 675 |
SubjectTerms | Animals Antineoplastic Agents - toxicity Body Weight - drug effects Cell Differentiation - drug effects Cell Line Cell Survival - drug effects Drug Evaluation, Preclinical Hematocrit Inhibitor of Apoptosis Proteins - metabolism Intestines - pathology Liver - pathology Mice Mice, Nude Original Paper ortho-Aminobenzoates - toxicity Repressor Proteins - metabolism Small molecule Sp1 Sp1 Transcription Factor - metabolism Stomach - pathology Survivin Tolfenamic acid Toxicity |
SummonAdditionalLinks | – databaseName: Karger Journals Open Access dbid: M-- link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8QwEA6iiF7Et-uLIB4N2jRNst7WooigCCp4K3nKYu0u6wr6750k3aKC17wKmaTzTTL5PoSOmaZSC2GIypUnTHFKtJZnRHCd58p4QXU4Gri949dP7Oa5eG7PO8JbmNeQ_xypUTtuAXC4p_HGi7HwWHyBCoDcIUmPkO6-oBD9dK-ZFURCGN1yCP3qGnh_WYgAgjD4DycUufrBAaVP_4GX0c1craKVFh_iQTLoGppzzTpaTIqRX-toqZwJtG2gpnR1HbJIsWosTo8q39-g8-Poc2gAXeORx4Dv8KCZDkkZzDvBD9CgxrdJFNedQNvauyhKjwdmaM-xwvcTR1q60Bpfdmzgm-jp6vKxvCatfAIxgIGmxBivLQSJQTewcPJMGvDHijPjpZUOHDtYx0ufUfj3aoBdVmjdN4WiinFtlMy30HwzatwOwrl3gEu4tYAnmGeFtErY3DDDuXBOsB46ms1nNU4sGVWMLop-1c1_D12Eme4aBGLrWDCavFTtPqmkZMpmjguRM6ayvrK5V4YWCoBrRg3voc1kp26Y2eD7f8rL-4tUVY2t76HtZNWuerYUdv8ZcA8t06h8EU5b9tH8dPLhDgB_TPVhXHrf9hnRZA priority: 102 providerName: Karger AG |
Title | Cellular and Organismal Toxicity of the Anti-Cancer Small Molecule, Tolfenamic Acid: a Pre-Clinical Evaluation |
URI | https://karger.com/doi/10.1159/000354471 https://www.ncbi.nlm.nih.gov/pubmed/24030139 https://doaj.org/article/884ad1e677344a19ad3fac25a15012c6 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS8MwGA0iiL6Il6nzRhAfDbNtbvNtFkWEiaCDvZVcYVi7MSfov_dL0xX1xRdf-pCmIXyn9Dtfkp6D0DnVqdRCGKIy5QlVPCVay0siuM4yZbxIdVgaGD7wuxG9H7PxN6uvcCYsygPHwPWkpMomjguRUaqSvrKZVyZlCphMkpootp2wZTHV7B8w0Y_7nAkjEsrqRlMIcnev3jyjVCQ_MlEt2A9Z6CWcv57_4ph1rrndQpsNScSDOLlttOKqHbQWbSM_d9B6vnRp20VV7soyHCXFqrI4_ln59goPP08_JgYoNp56DCQPD6rFhOQB4zl-gg4lHkZnXHcBfUvvamd6PDATe4UVfpw70miGlvimlQTvoNHtzXN-RxoPBWKACC2IMV5bqBSDeSBz8lIaSMqKU-OllQ6yO0DkpU9S-ABr4F5WaN03TKWKcm2UzPbQajWt3AHCmXdATri1QCqop0xaJWxmqOFcOCdoF50t41nMolRGUZcYrF-0Qe-i6xDptkNQt64bAPOiwbz4C_Mu6kSc2mGWgx__as8fr-OtYmZ9F-1HVNvbQYwwcODD_5jVEdpIa6-MsD5zjFYX83d3AoxloU_rlxOuQ0K-ANwh5ck |
link.rule.ids | 315,786,790,870,2115,27666,27955,27956 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cellular+and+organismal+toxicity+of+the+anti-cancer+small+molecule%2C+tolfenamic+acid%3A+a+pre-clinical+evaluation&rft.jtitle=Cellular+physiology+and+biochemistry&rft.au=Sankpal%2C+Umesh+T&rft.au=Lee%2C+Chris+M&rft.au=Connelly%2C+Sarah+F&rft.au=Kayaleh%2C+Omer&rft.date=2013-01-01&rft.eissn=1421-9778&rft.volume=32&rft.issue=3&rft.spage=675&rft_id=info:doi/10.1159%2F000354471&rft_id=info%3Apmid%2F24030139&rft.externalDocID=24030139 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1015-8987&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1015-8987&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1015-8987&client=summon |